Protagonist Therapeutics Inc (NASDAQ:PTGX) Expected to Post Quarterly Sales of $5.25 Million

Brokerages expect Protagonist Therapeutics Inc (NASDAQ:PTGX) to post $5.25 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Protagonist Therapeutics’ earnings. The highest sales estimate is $5.50 million and the lowest is $5.00 million. Protagonist Therapeutics reported sales of $2.35 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 123.4%. The company is expected to report its next earnings results on Tuesday, March 10th.

According to Zacks, analysts expect that Protagonist Therapeutics will report full-year sales of $4.81 million for the current fiscal year, with estimates ranging from $2.51 million to $8.90 million. For the next financial year, analysts forecast that the firm will post sales of $18.00 million, with estimates ranging from $16.00 million to $20.00 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Protagonist Therapeutics.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Wednesday, November 6th. The company reported ($0.61) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.71) by $0.10. Protagonist Therapeutics had a negative return on equity of 74.86% and a negative net margin of 209.02%. The business had revenue of $4.14 million for the quarter, compared to analysts’ expectations of $5.75 million.

Several analysts have issued reports on PTGX shares. ValuEngine raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. Nomura reissued a “buy” rating and set a $29.00 price target on shares of Protagonist Therapeutics in a research note on Sunday, August 11th. Zacks Investment Research upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a report on Tuesday, November 19th. Svb Leerink reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a research note on Tuesday, August 13th. Finally, BidaskClub lowered shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 9th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $19.60.

Shares of PTGX traded up $0.05 during midday trading on Tuesday, reaching $7.69. The stock had a trading volume of 490,321 shares, compared to its average volume of 315,904. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $207.85 million, a price-to-earnings ratio of -4.42 and a beta of 1.52. The company’s 50-day moving average is $10.59 and its 200 day moving average is $11.75. Protagonist Therapeutics has a 12-month low of $4.47 and a 12-month high of $16.67.

In related news, EVP Suneel Gupta acquired 30,000 shares of the stock in a transaction on Tuesday, December 3rd. The stock was purchased at an average price of $5.13 per share, for a total transaction of $153,900.00. Following the completion of the transaction, the executive vice president now owns 389,824 shares of the company’s stock, valued at approximately $1,999,797.12. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Bryan Giraudo acquired 8,000 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were bought at an average cost of $5.70 per share, with a total value of $45,600.00. Following the purchase, the director now owns 10,000 shares of the company’s stock, valued at approximately $57,000. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 39,175 shares of company stock worth $205,493. 14.20% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of PTGX. Rhumbline Advisers raised its holdings in Protagonist Therapeutics by 20.7% during the 3rd quarter. Rhumbline Advisers now owns 15,540 shares of the company’s stock valued at $187,000 after buying an additional 2,662 shares during the last quarter. California State Teachers Retirement System grew its holdings in Protagonist Therapeutics by 13.7% in the 3rd quarter. California State Teachers Retirement System now owns 26,542 shares of the company’s stock worth $319,000 after acquiring an additional 3,195 shares during the last quarter. Meeder Asset Management Inc. grew its holdings in Protagonist Therapeutics by 1,433.3% in the 3rd quarter. Meeder Asset Management Inc. now owns 3,450 shares of the company’s stock worth $41,000 after acquiring an additional 3,225 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Protagonist Therapeutics by 25.9% in the second quarter. Wells Fargo & Company MN now owns 20,553 shares of the company’s stock valued at $248,000 after acquiring an additional 4,224 shares during the period. Finally, Algert Global LLC increased its position in shares of Protagonist Therapeutics by 48.0% in the second quarter. Algert Global LLC now owns 15,517 shares of the company’s stock valued at $188,000 after acquiring an additional 5,030 shares during the period. 69.62% of the stock is currently owned by institutional investors.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Featured Article: Monthly Dividend Stocks Can Provide Solid Income

Get a free copy of the Zacks research report on Protagonist Therapeutics (PTGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.